0HUZ Stock Overview
A clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Imunon, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.05 |
52 Week High | US$3.63 |
52 Week Low | US$0.49 |
Beta | 2.13 |
11 Month Change | -8.97% |
3 Month Change | -13.74% |
1 Year Change | 14.33% |
33 Year Change | -92.26% |
5 Year Change | n/a |
Change since IPO | -97.33% |
Recent News & Updates
Recent updates
Shareholder Returns
0HUZ | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | 3.5% | 0.03% |
1Y | 14.3% | -15.8% | 8.5% |
Return vs Industry: 0HUZ exceeded the UK Biotechs industry which returned -16.2% over the past year.
Return vs Market: 0HUZ exceeded the UK Market which returned 8.7% over the past year.
Price Volatility
0HUZ volatility | |
---|---|
0HUZ Average Weekly Movement | 57.8% |
Biotechs Industry Average Movement | 6.4% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 9.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HUZ's share price has been volatile over the past 3 months.
Volatility Over Time: 0HUZ's weekly volatility has increased from 40% to 58% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1982 | 33 | Stacy Lindborg | imunon.com |
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Imunon, Inc. Fundamentals Summary
0HUZ fundamental statistics | |
---|---|
Market cap | US$14.98m |
Earnings (TTM) | -US$18.08m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs 0HUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0HUZ income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$359.30k |
Gross Profit | -US$359.30k |
Other Expenses | US$17.72m |
Earnings | -US$18.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.26 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 0HUZ perform over the long term?
See historical performance and comparison